Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03767595

ProACT Post-Approval Study

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of Colorado, Denver, Colorado, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is a male of at least 50 years of age.
  • Subject demonstrates stress urinary incontinence.
  • Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
  • Subject is willing and able to undergo surgical implantation of ProACT devices.
  • Subject is willing and able to comply with study-required

follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.

  • Subject is willing and able to sign the approved informed consent.
  • Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
  • Subject has a negative urine culture.
  • Subject has no known urogenital malignancy, other than previously treated prostate cancer.
  • Subject meets ONE of the following criteria:
  • Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
  • Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
  • Physician determines subject to be a suitable surgical candidate.

Exclusion criteria

  • Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
  • Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
  • Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
  • Subject has undergone radiation therapy in the prostatic area within the last 12 months.
  • Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
  • Subject has an atonic bladder.
  • Subject had, presently has, or is suspected of having bladder cancer.
  • Subject has untreated or unsuccessfully treated bladder stones.
  • Subject has detrusor sphincter dyssynergia.
  • Subject has known hemophilia or a bleeding disorder.
  • Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
  • Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.

Treatment and study plan

ProACT Adjustable Continence Therapy for Men

Device

The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.

Primary outcomes

  1. Urethral Strictures

    Time frame: 5 years

    Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up.

  2. Device Erosions

    Time frame: 5 years

    Cumulative incidence of ProACT device erosions over 5 years of follow-up.

  3. Incontinence Quality of Life Questionnaire (I-QoL)

    Time frame: 5 years

    Results on Validated Incontinence Quality of Life Questionnaire

Other outcomes

  1. Effect of ProACT on Subsequent Stress Urinary Incontinence(SUI) Therapy

    Time frame: 5 years

    This data will be collected with a "Post ProACT Explant Subsequent Therapy Questionnaire".

    This questionnaire will ask 3 questions regarding the ProACT therapy

    • Did the ProACT therapy have a detrimental effect on the difficulty of the subsequent implant surgery?
    • Did the ProACT therapy significantly increase the time required to implant the subsequent implant surgery?
    • Did the ProACT therapy increase the surgical complication rate during the subsequent implant surgery?

    The scale for each question is 0-1. 0 Meaning no effect (a "No" response on the questionnaire) and 1 being some effect ("Yes" response on the questionnaire). No effect (0) on subsequent SUI therapies is the better outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Patrick Gora

CONTACT

[email protected]

7636949880

Timothy C Cook, PhD

CONTACT

[email protected]

7636949880

Sponsors and collaborators

Lead sponsor

Uromedica

Industry

Registry information

Official study title

Post Approval Study of the ProACT™ Adjustable Continence Therapy for Men

Important dates

Study start
2019
Primary completion
2025
Study completion
2030
First posted
Dec 6, 2018
Registry last updated
Nov 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.